Pfizer’s Paxlovid COVID Pill Showed No Measurable Benefit in Adults 40 to 65: Study

A box of Paxlovid, Pfizer's COVID-19 pill, is seen in a file image. Jennifer Lorenzini/Reuters

A new study has found that Pfizer’s COVID-19 oral antiviral pill Paxlovid appears to provide little or no benefit for younger adults.

Researchers in the Israel-based study, which was published in the New England Journal of Medicine on Wednesday, examined over 109,000 patients between Jan. 9 and March 31 of this year.